BTCC / BTCC Square / Global Cryptocurrency /
ARK Invest Shifts Portfolio from Tech to Biotech in Strategic Rebalancing

ARK Invest Shifts Portfolio from Tech to Biotech in Strategic Rebalancing

Published:
2026-02-19 10:02:02
12
1
BTCCSquare news:

Cathie Wood's ARK Invest executed a series of notable trades on February 18, 2026, signaling a strategic pivot toward biotech equities. The firm allocated $4.33 million to Recursion Pharmaceuticals, acquiring 1,251,270 shares of the AI-driven drug discovery company. This follows accumulating positions in CRISPR Therapeutics, with 37,075 shares purchased for $1.97 million, reinforcing ARK's conviction in gene-editing technologies.

Concurrently, ARK divested from tech exposures, liquidating $3.89 million worth of PagerDuty shares and reducing stakes in Teradyne, DraftKings, and Salesforce. The moves reflect a calculated rotation into healthcare innovation at the expense of software and consumer discretionary holdings.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.